Used in pharmaceutical research as a potent and selective inhibitor of anaplastic lymphoma kinase (ALK). It shows high efficacy in targeting ALK-driven cancers, particularly non-small cell lung cancer (NSCLC) with ALK gene rearrangements. The compound demonstrates strong brain penetration, making it effective against central nervous system metastases. Its design allows for improved selectivity and reduced off-target effects, contributing to better patient tolerance in clinical settings. Often employed in the development of next-generation ALK inhibitors to overcome resistance mutations seen with earlier therapies.